Pharmacy

The ideal dry-eye drop: Through the eyes of clnicians, patients

February 15, 2010

Given the plethora of over-the-counter and prescription approaches available for dry eye, patient and clinician agreement on the appropriate regimen is key to treatment success.

Epinastine exhibits tolerability, efficacy in case study scenario

February 15, 2010

The multimodal anti-allergy agent epinastine hydrochloride 0.05% (Elestat, Inspire Pharmaceuticals) is an ideal treatment option for the management of seasonal allergic conjunctivitis and is a particularly good choice in patients who have dry eye disease as a comorbidity, according to Laurie D. Barber, MD

Update on branch retinal vein occlusion primary outcomes

February 01, 2010

Grid laser photocoagulation remains standard of care for eyes with ME secondary to BRVO.

Combination therapy may extend treatment effect of age-related macular degeneration

February 01, 2010

Many approaches for treating exudative age-related macular degeneration (AMD) have been developed.

1-year results show ongoing benefit of ranibizumab for diabetic macular edema

February 01, 2010

An updated analysis of data from an ongoing phase II study of intravitreal ranibizumab treatment for diabetic macular edema shows that functional and anatomic benefits observed at 6-month primary efficacy endpoint are generally maintained at 1 year after switching to a "prn" dosing schedule.

Radiation, injections reduce treatment burden for age-related macular degeneration

February 01, 2010

A preliminary study of epimacular brachytherapy showed that radiation and antivascular endothelial growth factor injections reduced the treatment burden in patients with neovascular age-related macular degeneration.

Alcon: Novartis offer 'inadequate'

February 01, 2010

Alcon Laboratories' Independent Director Committee is calling Novartis' merger proposal "grossly inadequate," and it is vowing to fight Novartis in its efforts to take control.

Implant is new approach to uveitis

February 01, 2010

A single sustained-release dexamethasone intravitreal implant resulted in resolution of inflammation and improvement in visual acuity (VA) in patients with intermediate or posterior uveitis through 26 weeks in a multicenter, randomized, controlled clinical trial.

Fixed-combination therapies are compared in studies

January 15, 2010

Pooled results from two randomized, investigator-masked parallel group clinical trials show that the fixed combination fo brimonidine tartrate 0.2%-timolol maleate 0.5% produced greater IOP lowering than the fixed combination of dorzolamidehydrochloride 2%-timolol maleate 0.5%, whether the fixed combination products were used alone or as an adjunct to treatment with a prostaglandin analogue.

Timolol is well-tolerated for further pressure control in glaucoma

January 15, 2010

Timolol maleate 0.5%/sorbitol complex is a convenient, well-tolerated choice for adjunctive therapy in patients taking a prostaglandin analogue who need further IOP control.